Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator

J Biol Chem. 2002 Feb 1;277(5):3150-7. doi: 10.1074/jbc.M109579200. Epub 2001 Oct 31.

Abstract

Cell migration is a fundamental aspect of the neoplastic cell metastasis. Here, we show that phosphatidylinositol (PI) 3-kinase is constitutively active and controls cell motility of highly invasive breast cancer cells by the activation of transcription factor, NF-kappaB. The urokinase-type plasminogen activator (uPA) promoter contains an NF-kappaB binding site, and uPA expression in MDA-MB-231 cells is induced by the constitutively active NF-kappaB. Thus, motility was inhibited by overexpression of a dominant negative p85alpha regulatory subunit of PI 3-kinase (p85DN), as well as by pretreatment of cells with specific inhibitors of the p110 catalytic subunit of PI 3-kinase, wortmannin and LY294002. The involvement of gene transcription in cell motility was suggested because treatment with actinomycin D and cycloheximide, which inhibit transcription and new protein synthesis, respectively, abolished endogenous migration of MDA-MB-231 cells. Although wortmannin, Ly294002, or overexpression of p85DN did not significantly reduce DNA binding activity of NF-kappaB in nuclear extracts, wortmannin, Ly294002, and the overexpression of p85DN or IkappaBalpha inhibited constitutive activation of NF-kappaB in a reporter gene assay. Highly invasive MDA-MB-231 cells constitutively secreted uPA in amounts significantly higher than poorly invasive MCF-7 cells. Furthermore, inhibition of NF-kappaB markedly attenuated endogenous migration, and inhibition of PI 3-kinase and NF-kappaB reduced secretion of uPA. Our data suggest a link between constitutively active PI 3-kinase, NF-kappaB, and secretion of uPA, which is responsible for the migration of highly invasive breast cancer cells. Thus, constitutively active PI 3-kinase controls cell motility by the regulation of expression of uPA through the activation of NF-kappaB.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Androstadienes / pharmacology
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / physiopathology*
  • Cell Movement / drug effects
  • Cell Movement / physiology*
  • Chloramphenicol O-Acetyltransferase / genetics
  • Chromones / pharmacology
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Enzyme Inhibitors / pharmacology
  • Female
  • Genes, Reporter
  • Humans
  • I-kappa B Proteins*
  • Morpholines / pharmacology
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / metabolism*
  • Neoplasm Invasiveness*
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Plasmids
  • Recombinant Fusion Proteins / metabolism
  • Transfection
  • Tumor Cells, Cultured
  • Urokinase-Type Plasminogen Activator / metabolism*
  • Wortmannin
  • beta-Galactosidase / genetics

Substances

  • Androstadienes
  • Chromones
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • I-kappa B Proteins
  • Morpholines
  • NF-kappa B
  • NFKBIA protein, human
  • Recombinant Fusion Proteins
  • NF-KappaB Inhibitor alpha
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Chloramphenicol O-Acetyltransferase
  • Phosphatidylinositol 3-Kinases
  • beta-Galactosidase
  • Urokinase-Type Plasminogen Activator
  • Wortmannin